Short Bowel Syndrome Market: By Drug Class, and Region
Global Short Bowel Syndrome market is valued at USD 1.18 Billion in 2022 and is projected to attain a value of USD 4.44 Billion by 2030 at a CAGR of 18.00% during the forecast period, 2022–2028. Due to the continuing COVID-19 outbreak, patients with gastrointestinal (GI) illnesses may be at an elevated risk of more severe sickness. Chronic inflammatory illness, comorbidity, and glucocorticoid use are all potential risk factors in these patients. Because healthcare is such an important business, producers in the short bowel syndrome market are required to maintain stable supply chains for treatment choices and pharmaceuticals in order to lower morbidity and death rates.
Short Bowel Syndrome Market Size, 2022 To 2030 (USD Billion)
Because of the widespread expression of angiotensin-converting enzyme 2 (ACE2) receptors in the colon, the GI tract may be susceptible to Coronavirus infection. As a result, firms in the short bowel syndrome market are expanding medication availability through online, hospital, and retail pharmacies in order to address patient needs and maintain income streams during the pandemic.
Rise in Prevalence of Short Bowel Syndrome
Report Coverage & Deliverables
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
- Power BI Report (Dashboard)
Short bowel syndrome has become more common in recent years all across the world. The rise in the number of patients on complete parenteral feeding can be linked to this. Short bowel syndrome is estimated to have a prevalence of four persons per million and a prevalence of three people per million. However, the exact prevalence of the disease is unknown; it is estimated based on the number of persons who receive parenteral feeding. The global market is expected to develop as the frequency and incidence of rare diseases rise. There are no approved medications for the treatment of short bowel syndrome in the world, and various additional therapies are being tested in clinical studies.
High Cost of Treatment
The expense of treating rare diseases is quite high, making therapy prohibitive for low-income individuals. Furthermore, the lack of funding in some countries makes the treatment inaccessible to a large number of people in the target population. In May 2019, the US Food and Drug Administration approved the use of Gattex for injection in children patients with short bowel syndrome aged 1 year and older. Gattex is an injectable medication that is used to treat adults with irritable bowel syndrome (IBS) (SBS). Treatment for Gattex is highly costly, costing approximately US$ 295,000 each year. Because rare diseases are life-threatening and do not have a permanent cure, the cost of therapy for a lifetime makes it expensive, resulting in a decrease in the number of patients preferring to avail the treatment.
The Short Bowel Syndrome market scope can be tabulated as below:
On the basis of Drug Class, the global Short Bowel Syndrome market is segmented into GLP-2, Growth Hormone, Glutamine and Others. Based on region, the Short Bowel Syndrome market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Below tree is interactive. You can click the nodes to get more information.
North America to Continue Dominating the Short Bowel Syndrome Market
Throughout the forecast period, North America is predicted to dominate the entire Short Bowel Syndrome Market. The Gattex, the only glucagon-like peptide-2 (GLP-2) analogue approved in the United States to increase intestinal absorption in patients with SBS, is largely responsible for this supremacy. In addition, the rise in sedentary lifestyles has resulted in less time to focus on nutritious and healthy food, resulting in increasing intake of unhealthy and junk food and the resulting intestinal diseases, which is a major driver driving market expansion in the region.
During the projected period, North America is expected to dominate the worldwide Short Bowel Syndrome market, followed by Europe. Increased adoption of technologically advanced Short Bowel Syndrome products, high healthcare expenditures, advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, a large number of Short Bowel Syndrome -based R&D projects, and the presence of a large number of leading Short Bowel Syndrome manufacturers in the region, as well as increased demand for genotyping products from pharmaceutical companies and rising government investments, by government bodies, are responsible for the large share of the North American Short Bowel Syndrome market.
Key participants operating in the Short Bowel Syndrome market are: TAKEDA Inc (Japan), Nutrinia (Netherlands), OxThera (Sweden), VectivBio AG (Switzerland), Ardelyx (US) are the major companies operating in Short Bowel Syndrome Market.
The Short Bowel Syndrome market is segmented as follows:
- Drug Class (GLP-2, Growth Hormone, Glutamine, Others)
- Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- TAKEDA Inc (Japan)
- Nutrinia (Netherlands)
- OxThera (Sweden)
- VectivBio AG (Switzerland)
- Ardelyx (US) are the major companies operating in Short Bowel Syndrome Market.
||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
||Avail of customized purchase options to meet your exact research needs. Explore purchase options